- Home
- WATT vs VCNX Comparison
WATT vs VCNX Comparison
Compare WATT & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- VCNX
- Stock Information
- Founded
- WATT 2012
- VCNX 2001
- Country
- WATT United States
- VCNX United States
- Employees
- WATT N/A
- VCNX N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- VCNX Health Care
- Exchange
- WATT Nasdaq
- VCNX Nasdaq
- Market Cap
- WATT 3.9M
- VCNX 4.5M
- IPO Year
- WATT 2014
- VCNX N/A
- Fundamental
- Price
- WATT $0.47
- VCNX $3.63
- Analyst Decision
- WATT Strong Buy
- VCNX
- Analyst Count
- WATT 2
- VCNX 0
- Target Price
- WATT $2.25
- VCNX N/A
- AVG Volume (30 Days)
- WATT 201.1K
- VCNX 115.4K
- Earning Date
- WATT 11-12-2024
- VCNX 11-14-2024
- Dividend Yield
- WATT N/A
- VCNX N/A
- EPS Growth
- WATT N/A
- VCNX N/A
- EPS
- WATT N/A
- VCNX N/A
- Revenue
- WATT $431,184.00
- VCNX $388,000.00
- Revenue This Year
- WATT $95.75
- VCNX N/A
- Revenue Next Year
- WATT $834.07
- VCNX N/A
- P/E Ratio
- WATT N/A
- VCNX N/A
- Revenue Growth
- WATT N/A
- VCNX N/A
- 52 Week Low
- WATT $0.45
- VCNX $1.39
- 52 Week High
- WATT $2.75
- VCNX $13.02
- Technical
- Relative Strength Index (RSI)
- WATT 32.37
- VCNX 55.50
- Support Level
- WATT $0.45
- VCNX $3.04
- Resistance Level
- WATT $0.58
- VCNX $3.95
- Average True Range (ATR)
- WATT 0.04
- VCNX 0.38
- MACD
- WATT -0.01
- VCNX 0.05
- Stochastic Oscillator
- WATT 12.96
- VCNX 70.37
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.